JTC Employer Solutions Trustee Ltd Purchases 390,045 Shares of Haleon plc (NYSE:HLN)

JTC Employer Solutions Trustee Ltd increased its stake in shares of Haleon plc (NYSE:HLN - Free Report) by 1,011.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 428,614 shares of the company's stock after buying an additional 390,045 shares during the quarter. Haleon comprises approximately 0.4% of JTC Employer Solutions Trustee Ltd's investment portfolio, making the stock its 27th biggest position. JTC Employer Solutions Trustee Ltd's holdings in Haleon were worth $4,408,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Sierra Ocean LLC bought a new position in Haleon during the 4th quarter worth $26,000. Geneos Wealth Management Inc. bought a new position in Haleon during the 4th quarter worth $35,000. Spire Wealth Management bought a new position in Haleon during the 4th quarter worth $39,000. FIL Ltd raised its position in Haleon by 45.7% during the 4th quarter. FIL Ltd now owns 4,049 shares of the company's stock worth $39,000 after purchasing an additional 1,270 shares during the last quarter. Finally, Addison Advisors LLC raised its position in shares of Haleon by 28.7% in the 4th quarter. Addison Advisors LLC now owns 4,954 shares of the company's stock worth $47,000 after acquiring an additional 1,106 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently commented on HLN shares. Wall Street Zen lowered Haleon from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Hsbc Global Res downgraded Haleon from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 5th. Morgan Stanley upgraded Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price target for the company in a research note on Friday, May 9th. BNP Paribas Exane upgraded Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price target for the company in a research note on Tuesday, May 27th. Finally, BNP Paribas upgraded Haleon to a "strong-buy" rating in a research note on Tuesday, May 27th. Six analysts have rated the stock with a hold rating, four have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, Haleon has a consensus rating of "Moderate Buy" and a consensus target price of $12.33.

Haleon Stock Performance

Shares of NYSE:HLN traded up $0.18 during mid-day trading on Thursday, reaching $11.11. The company had a trading volume of 10,123,917 shares, compared to its average volume of 13,343,209. The firm has a market cap of $50.02 billion, a price-to-earnings ratio of 32.68, a PEG ratio of 2.82 and a beta of 0.31. Haleon plc has a one year low of $8.24 and a one year high of $11.42. The company's 50-day moving average price is $10.46 and its 200-day moving average price is $10.01. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.